Genmab AS (GMAB)vsNovartis AG ADR (NVS)
GMAB
Genmab AS
$26.52
+1.57%
HEALTHCARE · Cap: $16.45B
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1421% more annual revenue ($56.58B vs $3.72B). GMAB leads profitability with a 25.9% profit margin vs 23.9%. GMAB appears more attractively valued with a PEG of 1.69. GMAB earns a higher WallStSmart Score of 54/100 (C-).
GMAB
Buy54
out of 100
Grade: C-
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+48.4%
Fair Value
$58.29
Current Price
$26.52
$31.77 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 26 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.0%
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Expensive relative to growth rate
3.0% revenue growth
Weak financial health signals
Earnings declined 94.4%
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : GMAB
The strongest argument for GMAB centers on Debt/Equity, Altman Z-Score, Profit Margin. Profitability is solid with margins at 25.9% and operating margin at 23.0%.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : GMAB
The primary concerns for GMAB are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
GMAB profiles as a value stock while NVS is a declining play — different risk/reward profiles.
GMAB carries more volatility with a beta of 0.74 — expect wider price swings.
GMAB is growing revenue faster at 3.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
GMAB scores higher overall (54/100 vs 51/100), backed by strong 25.9% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Genmab AS
HEALTHCARE · BIOTECHNOLOGY · USA
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?